Name: Pfizer execs say there's a 'significant opportunity' to hike prices of its COVID vaccine
Brand: businessinsider.com
SKU: businessinsider-com-881
Availability: OnlineOnly

critic

Pfizer execs say there's a 'significant opportunity' to hike prices of its COVID vaccine

preview

Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.An icon in the shape of a person's head and shoulders. It often indicates a user profile.Redeem nowSign up for our newsletter to receive our top stories based on your reading preferences — delivered daily to your inbox.Something is loading.Pfizer execs have informed the company's investors of a "significant opportunity" to hike the prices of the Pfizer-BioNTech vaccine.Speaking at the virtual Barclays Global Healthcare Conference last week, two high-ranking Pfizer employees – CFO Frank D'Amelio and Chuck Triano, senior VP of investor relations – said there would be a chance for Pfizer to raise prices for the vaccine when COVID moves from a pandemic state to an endemic situation and the virus circulates continually in pockets around the globe."If you look at how current demand and current pricing is being driven, it's clearly not being driven by what I'll call normal market conditions or normal market forces... it's been driven by the pandemic state we've been in, and the needs of governments to secure doses from various vaccine suppliers," said D'Amelio.&nbsp;He added that with the resumption of "normal market conditions" over time, there would then be a chance for the company to take advantage of opportunities from "a demand...and pricing perspective."&nbsp;—Lee Fang (@lhfang) &nbsp;The two added that to stay protected, people may need a third dose of the vaccine to bolster immunity and efficacy against emerging COVID variants.In addition to regular yearly boosters, this vaccination cycle may become part of the new normal."We believe it's becoming increasingly likely that an annual re-vaccination is going to take place," said D'Amelio, noting that the company did not see the pandemic or the resulting vaccination drives as a "onetime event."The company is planning to accelerate the number of vaccine doses it can deliver by the end of July by ramping up production and supply chain capabilities.&nbsp;D'Amelio said Pfizer was initially supposed to deliver 100 million doses of the vaccine to the US government by the end of March. The company is now on track to deliver 120 million doses by the end of the month and 200 million doses by May."For the full year, we had originally said we thought we could do 1.3 billion doses. We're now at 2 billion doses. And obviously, we're working to improve upon that number as well," he said.Sign up for notifications from Insider! Stay up to date with what you want to know.Subscribe to push notificationsAn icon in the shape of a lightning bolt.Keep readingTwo crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.An icon in the shape of a person's head and shoulders. It often indicates a user profile.Redeem nowSign up for our newsletter to receive our top stories based on your reading preferences — delivered daily to your inbox.Something is loading.Pfizer execs have informed the company's investors of a "significant opportunity" to hike the prices of the Pfizer-BioNTech vaccine.Speaking at the virtual Barclays Global Healthcare Conference last week, two high-ranking Pfizer employees – CFO Frank...

public

Cheryl Teh

What you want to know about business. A section of @thisisinsider. Follow us on Facebook, Instagram, and YouTube. Visit our homepage for the day's top stories.

businessinsider.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

Pfizer execs say there's a 'significant opportunity' to hike prices of its COVID vaccine

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS